Impact News +++ HSBC downgrades Estée Lauder as recovery priced in for now (Investing.com) +++ ESTEE LAUDER Aktie +3,08%

QUEST DIAGNOSTICS Aktie

>Aktienkurs

165 EUR +2.7% (TradegateBSX)

Ask: 171.9 EUR / 180 Stück

Bid: 170.2 EUR / 180 Stück

Tagesumsatz: 109 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: +1,3%

1 Monat: +4,9%

3 Monate: +4,2%

6 Monate: +5,4%

1 Jahr: +2,9%

laufendes Jahr: +7,4%

>QUEST DIAGNOSTICS Aktie

Name:

QUEST DIAGNOSTICS DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US74834L1008 / 904533

Symbol/ Ticker:

QDI (Frankfurt) / DGX (NYSE)

Kürzel:

FRA:QDI, ETR:QDI, QDI:GR, NYSE:DGX

Index:

S&P500

Webseite:

http://www.questdiagnosti..

Profil:

Quest Diagnostics Inc. is a leading healthcare com..
>Volltext..

Marktkapitalisierung:

18106.33 Mio. EUR

Unternehmenswert:

23261.52 Mio. EUR

Umsatz:

9183.55 Mio. EUR

EBITDA:

1816.4 Mio. EUR

Nettogewinn:

815.09 Mio. EUR

Gewinn je Aktie:

7.31 EUR

Schulden:

5401.79 Mio. EUR

Liquide Mittel:

365.65 Mio. EUR

Operativer Cashflow:

1595.48 Mio. EUR

Bargeldquote:

0.2

Umsatzwachstum:

7.92%

Gewinnwachstum:

9.04%

Dividende je Aktie:

2.75 EUR

Dividendenrendite:

1.66%

Dividendenschätzung:

1.66%

Div. Historie:

13.01.26 - 0.6868€
03.10.25 - 0.6864€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

QUEST DIAGNOSTICS, QUEST DIAGNOSTIC

Letzte Datenerhebung:

10.02.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 111.24 Mio. St.

Frei handelbar: 99.54%

Leerverk. Aktien: 5.14%

Rückkaufquote: 1.02%

Mitarbeiter: 56000

Umsatz/Mitarb.: 0.15 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 3.78%

Bewertung:

KGV: 22.22

KGV lG: 19.31

KUV: 1.99

KBV: 2.9

PEG-Ratio: 1.55

EV/EBITDA: 12.81

Rentabilität:

Bruttomarge: 32.05%

Gewinnmarge: 8.88%

Operative Marge: 14.62%

Managementeffizenz:

Gesamtkaprendite: 5.96%

Eigenkaprendite: 13.69%

>Peer Group

Gesundheit

>Chart & Kurs - NYSE

>Alle News

10.02.26 - 17:36	Quest Diagnostics (DGX) Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

10.02.26 - 16:54	Quest Diagnostics hits 52-week high as outlook tops consensus (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.02.26 - 16:12	Quest Diagnostics übertrifft Erwartungen in Q4 2025 – Aktie legt zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.02.26 - 15:15	Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates (Zacks)
	Quest Diagnostics (DGX) delivered earnings and revenue surprises of +2.85% and +2.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

10.02.26 - 13:24	Quest Diagnostics Boosts Dividend 7.5%, Adds $1 Bln To Buyback Program (AFX)
	WASHINGTON (dpa-AFX) - Quest Diagnostics Inc. (DGX) on Tuesday said its board has approved a 7.5% increase in the quarterly cash dividend to $0.86 per share from $0.80 per share.The dividend will ......

10.02.26 - 13:24	Quest Diagnostics Profit Climbs In Q4 (AFX)
	WASHINGTON (dpa-AFX) - Quest Diagnostics (DGX) announced earnings for its fourth quarter that Increases, from last yearThe company's earnings totaled $245 million, or $2.18 per share. This compare......

10.02.26 - 12:54	Quest Diagnostics beats Q4 estimates (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.02.26 - 12:51	Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share (PR Newswire)
	Fourth quarter revenues of $2.81 billion, up 7.1% from 2024 Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024 Full year revenues of $11.04 billion, up 11.8% from 2024 Full year reported diluted EPS......

10.02.26 - 12:42	Quest Diagnostics raises quarterly dividend by 7.5% to $0.86, announces $1B buyback (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.02.26 - 12:36	Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization (PR Newswire)
	SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from......

09.02.26 - 17:48	Quest Diagnostics Q4 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.02.26 - 17:30	Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term (Zacks)
	Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

06.02.26 - 17:30	Here′s How Quest Diagnostics Is Placed Ahead of Q4 Earnings (Zacks)
	DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and consumer testing....

05.02.26 - 16:15

Cleveland Diagnostics Names Jack Kenny as Chairman of the Board (Business Wire)

Seasoned industry executive brings proven leadership to support commercial scale of IsoPSA® Assay & platform expansionCLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, today announced the appointment of Jack Kenny as Chairman of the Board of Directors. Kenny joins the company at a pivotal time as Cleveland Diagnostics accelerates commercial growth following recent FDA approval of its IsoPSA® IVD Assay and expands its broader IsoClear™ platform. Kenny brings more than three decades of operational, commercial, and board-level leadership experience across the diagnostics and life sciences industries. He has deep expertise in the in vitro diagnostics, molecular, and laboratory services sectors. Most recently, he served as Chief Executive Officer of Meridian Bioscience. His prior leadership roles include senior executive positions at Siemens Healthcare, Becton Dickinson Diagnostics, Danaher, and Quest Diagnostics, as well as current and past...

02.02.26 - 14:54	Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease (PR Newswire)
	New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a......

21.01.26 - 20:39	Quest Diagnostics Named to Fortune′s World′s Most Admired Companies List for 12th Consecutive Year (PR Newswire)
	SECAUCUS, N.J., Jan. 21, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been named to the Fortune® magazine 2026 World's Most Admired Companies™ list, for the 12th consecutive year. "Quest's......

08.01.26 - 16:03	Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026 (PR Newswire)
	SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will......

07.01.26 - 17:30	Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

06.01.26 - 16:03	Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
	SECAUCUS, N.J., Jan. 6, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026......

05.01.26 - 15:01	Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan (PR Newswire)
	Quest also now provides comprehensive Collaborative Lab Solutions (Co-Lab) hospital lab management services for all 21 Corewell Health hospitals SOUTHFIELD, Mich. and GRAND RAPIDS, Mich. and SECAUCUS, N.J., Jan. 5, 2026 /PRNewswire/ -- Corewell Health and Quest Diagnostics (NYSE: DGX)......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das Gegenwärtige ist begrenzt. Das Mögliche ist unermeßlich. - Abraham Lincoln

Partner: >TradegateBSX Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram